Assessment of socio-economic deprivation impact on breast cancer prognosis : results of a case-control study

Contexte : Les inégalités sociales de santé représentent un problème de santé publique considérable. Dans le cadre du cancer du sein, la précarité est associée au pronostic. En effet, une relation entre précarité géographique et stade au diagnostic a été établie dans la littérature. Cependant, à ce jour, aucune étude n'a encore analysé l'association de ce dernier à la précarité individuelle.Objectifs : Les objectifs de ce travail de recherche sont (1) d'estimer le risque de cancer du sein de stade avancé associé à la précarité individuelle, (2) d'étudier l'impact des facteurs pouvant modifier ce risque, (3) d'évaluer la robustesse de l'association face au choix de la mesure de précarité.Population et méthode : Les données sont issues d'une étude cas-témoins. Les Cas et les Témoins de l'étude ont été recrutés parmi les patientes de l'Hérault atteintes de cancers du sein invasifs diagnostiqués entre 2011 et 2012. Les Cas correspondent aux patientes présentant un cancer du sein de mauvais pronostic (taille de tumeur supérieure à 5cm, ou atteinte ganglionnaire ou atteinte métastatique) et les Témoins aux patientes présentant des cancers de bon pronostic (taille de tumeur inférieure à 5cm et aucune atteinte ganglionnaire et aucune atteinte métastatique). Au total 604 patientes ont été incluses : 173 Cas et 431 Témoins. L'exposition à la précarité a été recueillie par un questionnaire standardisé.Résultats : Les patientes précaires ont, toutes variables égales par ailleurs, 2 fois plus de risque d'avoir un cancer de stade avancé comparée aux patientes non précaires. La précarité n'est associée à aucun autre facteur biologique (grade SBR, types histologique et moléculaire). Chez les patientes asymptomatiques (diagnostiquées suite à un dépistage) les patientes précaires ont plus de risque d'avoir des cancers de stade avancé. Chez les femmes avec un antécédent familial de cancer du sein tout comme chez les femmes vivant dans une zone géographique favorisée, les patientes précaires et non-précaires ont le même risque de cancer de stade avancé. Comparé aux autres mesures de l'environnement socio-économique (classe sociale, précarité géographique…), le score EPICES semble la méthode de mesure la plus adaptée pour étudier l'association entre précarité et stade au diagnostic.Conclusion : Nos résultats suggèrent que les écarts observés entre les patientes précaires et les patientes non-précaire semblent être plutôt liés à retard au diagnostic plutôt qu'à des différences biologiques entre les tumeurs. Ce retard au diagnostic semble dépendre de composantes individuelles mais aussi collectives. De plus, une meilleure connaissance du cancer du sein pourrait permettre de réduire les barrières supplémentaires vécues par les précaires.Context: Socio-economic inequalities in health represent a significant public health problem. In the breast cancer context, socio-economic deprivation is associated with prognosis. Indeed, a relationship between area-based deprivation and diagnostic stages was already described in the international literature. However, the association between individual deprivation and diagnostic stages was not study so far.Objectives: Our aim was to (1) estimate the risk of advanced breast cancer associated with individual socio-economic deprivation, (2) study the impact of modifying factors, (3) evaluate the strength of this association according to the method used to measure deprivation.Population and methods: Data were collected from a Case-Control study. Cases and Controls were recruited among invasive breast cancer patients diagnosed between 2011 and 2012 in the Hérault. Cases were defined as patients with poor prognosis breast cancer (with tumor size over 5cm, or with lymph node involvement, or with metastasis). Controls were defined as patients with good prognosis breast cancer (with tumor size under 5cm, and without lymph node involvement, and without metastasis). A total number of 604 patients were included: 173 Cases and 431 Controls. The exposition to deprivation was measured by a standardized questionnaire.Results: Deprived patients, with all other variables remaining constant, have a two-fold risk of having advanced breast cancer compared to non-deprived patients. Deprivation was not associated with the other biological factors (SBR grade, histologic and molecular type). Among asymptomatic patients (diagnosed after a mammographic screening), deprived patients have a higher risk of advanced breast cancer. Among women with family history of breast cancer so as women living in affluent geographic areas, deprived and non-deprived patients have the same risk of advanced breast cancer. Compared to other measures of socio-economic environment (social class, area-based deprivation…), EPICES score seems to be the most adapted method to study the association between deprivation and breast cancer diagnostic stages.Conclusion: Our results suggest that the gap observed between deprived and non-deprived patients seem to be associated with delayed diagnosis more than biological differences between tumors. This delayed diagnosis seems depend on individual and geographic components. Moreover, a better knowledge of breast cancer could allow a reduction of the barrier experienced by deprived women

Prognostic Relevance of Viable Circulating Tumor Cells Detected by EPISPOT in Metastatic Breast Cancer Patients

International audienceBackground: Detection of circulating tumor cells (CTC) in breast cancer patients is currently performed in many clinical trials, using different technologies, in particular the EpCAM-dependent CellSearch® system. The purpose of this study was to investigate the incidence and prognostic relevance of viable CTC in a large cohort of metastatic breast cancer (MBC) patients.Methods: A total of 254 MBC patients were enrolled in a prospective multicenter study at first diagnosis of metastatic disease or disease progression (before the start of a new treatment regimen). After EpCAM-independent enrichment, viable CTC releasing cytokeratin-19 as an epithelial cell marker were detected in the peripheral blood by an EPISPOT assay, and the Food and Drug Administration cleared CellSearch was used as the reference method.Results: Using the EPISPOT assay, CTC were detected in 59% of MBC patients. The overall survival (OS) was linked with the CTC status measured by EPISPOT (P = 0.0191), which allowed stratification of MBC patients in low- and high-risk groups. This stratification could be improved by addition of the CTC status assessed by the CellSearch system. In multivariate Cox proportional-hazards regression analysis, the 3 methods used to determine the level of CTC (EPISPOT, CellSearch, and combination of EPISPOT/CellSearch) were compared by the Bayesian information criterion method. Interestingly, the combination of the EPISPOT and CellSearch assays was the strongest predictor of OS (hazard ratio, 22.6; 95% CI, 2.8-184.08).Conclusions: This is the first study in which CTC detection using the EPISPOT assay was evaluated on a large cohort of MBC patients, showing prognostic relevance of the presence of viable CTC

Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival

International audienceEpstein–Barr virus reactivation (EBV-R) frequently occurs in patients having allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated the impact of controlled EBV-R on survival of 190 patients (114M/76F, median age: 51 yr, range 18–69), having HSCT for hematological malignancies (105 acute leukemias and myelodysplasias, 71 lymphoproliferative disorders, 14 others). Overall survival (OS) and progression-free survival (PFS) were compared between patients with and without EBV-R. Of 138, patients had reduced-intensity conditioning regimen. Various stem cell sources (141 PB, 33 umbilical cord blood and 16 bone marrow) were used. Patients with EBV-R had longer PFS and OS than those without EBV-R: PFS at 2 yr 69% vs. 51% and at 5 yr 47% vs. 38% (P < 0.04); OS at 2 yr 76% vs. 64% and at 5 yr 63% vs. 47%) (P < 0.001). The use of rituximab had no impact on OS and PFS, but it reduced the intensity of GVHD, despite the fact that TRM was not significantly different between the two groups of patients. So, rituximab may have an additional effect to other factors on PFS and OS. In multivariate analysis, antithymocyte globulin administration was not a significant factor for PFS (P = 0.68) and for OS (P = 0.81). Circulating NK cells were significantly increased by 22% (P = 0.03) in EBV-R patients with no differences for other parameters. Controlled EBV-R in the setting of HSCT is associated with better OS and PFS, with a significant increase in circulating NK cells

Homology study showed that this amino acid was highly conserved through species for the c.1651G>C mutation.

<p>Homology study showed that this amino acid was highly conserved through species for the c.1651G>C mutation.</p